Accuray Incorporated (ARAY) Fair Value 2026

ARAY · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Accuray Incorporated (ARAY) trades at $0.26, versus a $1.31 median fair value across its 2 active models — 398.9% above the current price. QOC: 6.9/10. Value Trap Risk: 26/100 (LOW). 2/13 models active.

Key Facts

Ticker
ARAY
Price
$0.26
Quality Score
6.9/10
Value Trap Risk
26/100
Models Active
2/13
Last Updated
Strength: EROIC Spread suggests +452.0% upside with 70% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Accuray Incorporated (ARAY) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Accuray Incorporated (ARAY) appears undervalued as of : the median of 2 independent fair value estimates is $1.31, 398.9% above the current price of $0.26. Estimates range from $1.17 to $1.45. ARAY scores 6.9/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ARAY’s +398.9% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Accuray Incorporated Stock in 2026? →

What Fair Value Does Each Model Give ARAY?

2 Intrinsic Value Models vs. Current Price ($0.26)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
$1.45 +452.0%
Hybrid · High Conviction
$1.17 +345.8%

All Models Active

All 2 models are displayed above.

What Is Accuray Incorporated (ARAY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Accuray Incorporated's intrinsic value is estimated at a median fair value of $1.31. At a current market price of $0.26, 2 of 2 active valuation models identify upside potential, projecting a median implied return of +398.9%. Notably, EROIC sees the most upside at +452.0% (fair value: $1.45), while Sentiment SOTP is the most conservative at +345.8% ($1.17). The spread between these extremes — +106.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About ARAY?

2 of 13 models are currently active for ARAY. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for ARAY is $1.31 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ARAY Rank in Medical Devices?

Among 157 Medical Devices stocks, ARAY ranks #54 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Accuray Incorporated competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ARAY a Value Trap?

CirclFi's Value Trap algorithm assigns ARAY a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Accuray Incorporated. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Accuray Incorporated is rated at 6.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +106.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ARAY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ARAY's 2 active models, average confidence is 61%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Accuray Incorporated Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

Read investment analysis: CTKB · ATEC · CERS · NEOG · PRCT · SENS · LAB · PAVM · ESMC · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to ARAY?

7 companies across all industries closest to ARAY’s Quality of Company score of 6.9/10.

Read investment analysis: LSF · FHTX · CLFD · MNRO · CIM · LCTX · NVDA

Where Does ARAY Sit in CirclFi's Medical Devices Rankings?

ARAY is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Accuray Incorporated’s Valuation?

What is Accuray Incorporated's intrinsic value in 2026?

CirclFi puts Accuray Incorporated (ARAY)'s intrinsic value at $1.31 — the median of 2 independent model estimates as of 2026-08-27, ranging from $1.17 to $1.45. The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ARAY overvalued or undervalued right now?

At $0.26, 2 of 2 active models suggest ARAY may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $1.31, 398.9% above the current price of $0.26 — a consensus view that ARAY is undervalued. The assessment depends on which methodology best fits Accuray Incorporated's business model in Medical Devices.

What does a Quality of Company score of 6.9 mean for ARAY?

Accuray Incorporated's QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ARAY?

CirclFi analyzes ARAY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ARAY a value trap in 2026?

Accuray Incorporated's Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Accuray Incorporated (ARAY) has a median fair value of $1.31 — 398.9% above the current price of $0.26 — as of 2026-08-27.” Source: circlfi.com/stock/ARAY/ · Methodology
Primary sources for this ARAY valuation
  • Financial statements: Accuray Incorporated 10-K and 10-Q filings on SEC EDGAR (CIK 0001138723) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ARAY as of ; valuations recomputed .